Liminal BioSciences Inc. Common Shares
LMNL
LMNL: Liminal Biosciences Inc is a clinical stage biopharmaceutical company focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases using our drug discovery platform and a data driven approach. The company has active business operations in Canada and the United Kingdom.
moreShow LMNL Financials
Recent trades of LMNL by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by LMNL's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Substituted aromatic compounds and related method for the treatment of fibrosis Dec. 13, 2022
-
Patent Title: Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis Nov. 30, 2021
-
Patent Title: Phenylketone carboxylate compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis Feb. 23, 2021
-
Patent Title: Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration Dec. 22, 2020
Federal grants, loans, and purchases
Followers on LMNL's company Twitter account
Number of mentions of LMNL in WallStreetBets Daily Discussion
Recent insights relating to LMNL
Recent picks made for LMNL stock on CNBC
ETFs with the largest estimated holdings in LMNL
Flights by private jets registered to LMNL